MEK162 vs Dacarzabine in NRAS mutation postive melanoma patients

• Research type

  Research Study

• Full title

  The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus Dacarbazine in patients with advanced unresectable or metastatic NRAS mutation positive melanoma

• IRAS ID

  124090

• Contact name

  James Larkin

• Contact email

  james.larkin@rmh.nhs.uk

• Sponsor organisation

  Array BioPharma Inc.

• Eudract number

  2012-003593-51

• ISRCTN Number

  xx

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  13/LO/0720

• Date of REC Opinion

  4 Jul 2013

• REC opinion

  Further Information Favourable Opinion